430 related articles for article (PubMed ID: 23394094)
1. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?
Musso G; Anty R; Petta S
Curr Pharm Des; 2013; 19(29):5297-313. PubMed ID: 23394094
[TBL] [Abstract][Full Text] [Related]
2. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
3. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
4. Current pharmacological treatment of nonalcoholic fatty liver.
Portincasa P; Grattagliano I; Palmieri VO; Palasciano G
Curr Med Chem; 2006; 13(24):2889-900. PubMed ID: 17073635
[TBL] [Abstract][Full Text] [Related]
5. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
6. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.
Musso G; Cassader M; Rosina F; Gambino R
Diabetologia; 2012 Apr; 55(4):885-904. PubMed ID: 22278337
[TBL] [Abstract][Full Text] [Related]
7. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.
Nseir W; Mograbi J; Ghali M
Dig Dis Sci; 2012 Jul; 57(7):1773-81. PubMed ID: 22419057
[TBL] [Abstract][Full Text] [Related]
8. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.
Musso G; Gambino R; Cassader M; Pagano G
Hepatology; 2010 Jul; 52(1):79-104. PubMed ID: 20578268
[TBL] [Abstract][Full Text] [Related]
10. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Angelico F; Burattin M; Alessandri C; Del Ben M; Lirussi F
Cochrane Database Syst Rev; 2007 Jan; (1):CD005166. PubMed ID: 17253544
[TBL] [Abstract][Full Text] [Related]
11. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
Park SH
Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease and lipids.
Wierzbicki AS; Oben J
Curr Opin Lipidol; 2012 Aug; 23(4):345-52. PubMed ID: 22617751
[TBL] [Abstract][Full Text] [Related]
13. Vitamin E and nonalcoholic fatty liver disease.
Pacana T; Sanyal AJ
Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
[TBL] [Abstract][Full Text] [Related]
14. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S
Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
[TBL] [Abstract][Full Text] [Related]
15. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
16. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis.
Lirussi F; Azzalini L; Orando S; Orlando R; Angelico F
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD004996. PubMed ID: 17253535
[TBL] [Abstract][Full Text] [Related]
17. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Stein LL; Dong MH; Loomba R
Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease from pathogenesis to management: an update.
Musso G; Gambino R; Cassader M
Obes Rev; 2010 Jun; 11(6):430-45. PubMed ID: 19845871
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease.
Smith BW; Adams LA
Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
[TBL] [Abstract][Full Text] [Related]
20. Involvement of free radicals and oxidative stress in NAFLD/NASH.
Sumida Y; Niki E; Naito Y; Yoshikawa T
Free Radic Res; 2013 Nov; 47(11):869-80. PubMed ID: 24004441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
